Address
Novartis Venture Funds
Novartis International AG WSJ-200.220 P.O. Box
4002 Basel
Switzerland
Phone
Industry
Business classification
Tags
VCID: 30987
Profile
Corporate information
Official name
Novartis International AG
Registration country
Investment activity status
Active investor
Company type
The corporate venturing arm of Novartis.Team
Current employees
![[node:title] photo](/sites/default/files/styles/icon/public/default_images/icon-person.png?itok=8SSzz6Wf "[node:title] photo"){kind=icon}
|
Florent Gros | ||
|
|
Rudolf Gygax |
Investments
Selected investments
| Company | Country | Date | Notes | ||
|---|---|---|---|---|---|
|
Tokai Pharmaceuticals Inc Developer of prostate cancer drugs |
United States | 15 May 2013 | Series E Active |
|
|
|
Opsona Therapeutics Ltd Innate immune drug development company |
Ireland | 29 Apr 2013 | Series C Active |
|
|
|
Aerpio Therapeutics Inc |
United States | 1 Aug 2012 | Series A Active |
|
|
|
BioRelix Inc Advanced fight against drug resistant microbes by attacking novel targets with novel drugs. |
United States | 4 Jun 2007 22 Mar 2012 |
N/A Follow-on investment. Active |
|
|
|
Pulmatrix Inc Discovering a new class of host-targeted therapies that pathogen independently treat |
United States | 1 Aug 2011 | Series B |
|
|
Akebia Therapeutics Inc |
United States | 1 Apr 2011 1 Sep 2009 |
Series B Active |
|
|
|
Cylene Pharmaceuticals Inc Clinical stage private company developing small molecule drugs against newly validated cancer targets. |
United States | 1 Sep 2010 | Series D Active |
|
|
|
Anchor Therapeutics Inc |
United States | 1 Aug 2010 | Series B |
|
|
|
FoldRx Pharmaceuticals Inc |
United States | 1 Jun 2010 | N/A |
|
|
|
Microchips Inc Developer and tester of implanted devices for people with chronic conditions. |
United States | 1 Jan 2010 | N/A Active |
|
|
|
PharmAbcine Inc Develops fully human therapeutic monoclonal antibody (mAb) |
South Korea | 1 Sep 2009 | Series A |
|
|
|
Intellikine |
United States | 1 Jul 2009 | Series B Active |
|
|
|
Visiogen Inc A medical device company focused on dual-optic accommodating intraocular lens, called Synchrony, for the treatment of age-related vision loss. |
United States | 1 May 2009 | Series D Initial investment. Round participant. Active |
|
|
|
Heptares Therapeutics Ltd |
United Kingdom | 1 Feb 2009 | Series A |
|
|
|
Intradigm Corp |
United States | 1 Jan 2009 | Series B |
|
|
|
Catalyst Biosciences Inc Developer of catalytic biopharmaceutical products based on engineered human proteases. |
United States | 1 Dec 2008 | Series C |
|
|
|
ESBATech AG Switzerland based Biomedical Research Unit of Alcon |
Switzerland | 1 Aug 2008 | Series B Initial investment. Round participant. Active |
|
|
|
Ascent Therapeutics Inc |
United States | 1 Nov 2007 | Series A |